Brochure | October 23, 2023

INDe sgRNA Manufacturing

GettyImages-1386852216 cell therapy

Move your CRISPR-based therapeutics from discovery to delivery in a seamless transition with IND-enabling (INDe) sgRNAs. These INDe sgRNAs are designed specifically for preclinical safety, toxicity, and efficacy studies where the use of high quality sgRNAs with increased quality oversight and documentation can enable a successful IND submission. Synthego’s custom manufacturing team and dedicated INDe facility will help you proceed through your CRISPR therapeutic development process.

access the Brochure!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

Synthego Corporation